Oral Sprays Market to Reach USD 504.3 Million by 2032

According to analysts at Vantage Market Research, the Global Oral Sprays Market size is worth USD 404.2 Million in 2023 and is projected to reach USD 504.3 Million by 2032, growing at a CAGR (Compound Annual Growth Rate) of 1.6% from 2024 to 2032. Market Key trends include innovation in spray formulations, rising adoption of natural ingredients, expanding applications in healthcare and wellness, and growing preference for portable, on-the-go oral care solutions.

Market Overview

As consumers increasingly seek user-friendly healthcare solutions, oral sprays have emerged as a preferred alternative to traditional dosage forms like pills and syrups. Their compact size and portability make them ideal for on-the-go use, allowing individuals to manage health conditions quickly and discreetly.  Their compact size and portability make them ideal for on-the-go use, allowing individuals to manage health conditions quickly and discreetly. The straightforward administration process, requiring no water or special preparation, enhances patient compliance and adherence to treatment regimens.

The growing use of natural and herbal formulations is driven by increasing consumer preference for eco-friendly, chemical-free products, emphasizing health benefits, sustainability, and transparency in personal care, wellness, and pharmaceuticals. Additionally, Technological advancements in spray formulations have revolutionized various industries, particularly pharmaceuticals, cosmetics, and agriculture. Innovations such as nano-spray technology, microencapsulation, and aerosol systems have improved the precision, efficacy, and safety of sprays. These advancements allow for better targeting, controlled release, and enhanced absorption of active ingredients, leading to more effective treatments and applications.

MGC Pharma and HempStreet entered a collaboration to launch ArtemicC

• In January 2023, MGC Pharma has partnered with HempStreet to launch ArtemicC, a nutraceutical mouth spray aimed at alleviating Covid-19 symptoms. This spray has shown promise in improving recovery times for Covid-19 patients. MGC Pharma specializes in cannabis-based and phytopharmaceutical formulations, with a focus on polyherbal solutions

Key Takeaways from the Report

• In 2023, North America dominated the market with 38.2% market share. Market is driven by factors such as deeper product penetration and higher consumer awareness rate
• By type, the drug oral spray segment is dominated the market in 2023. The segment is driven by rising consumer preference for non-invasive drug delivery systems, advancements in spray technology, and growing adoption in both over-the-counter and prescription medications
• Based on Application, the medicine segment is dominated the market is 2023. The highest industry growth was observed in the medicine segment as oral sprays are commonly used to deliver several medicines including throat sprays and oral healthcare products

Top Companies

• Johnson and Johnson
• Sunstar
• Lion Corporation
• Dr Fresh Inc
• GalxoSmithKline
• PeriProducts
• Hello Products LLC
• Oral Labs
• Philips

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Johnson and Johnson are seeking approval for its SPRAVATO (esketamine) CIII nasal spray

• In July 2024, Johnson & Johnson has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for its SPRAVATO (esketamine) CIII nasal spray as a treatment for treatment-resistant depression (TRD)